-
1
-
-
0036178410
-
Amphotericin B: Spectrum and resistance
-
Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(Suppl 1):7-10.
-
(2002)
J Antimicrob Chemother
, vol.49
, Issue.SUPPL. 1
, pp. 7-10
-
-
Ellis, D.1
-
2
-
-
0035835901
-
Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial
-
Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J. 2001;322:579-82.
-
(2001)
Br Med J
, vol.322
, pp. 579-582
-
-
Eriksson, U.1
Seifert, B.2
Schaffner, A.3
-
3
-
-
0036681666
-
Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study
-
Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis. 2002;186:379-88.
-
(2002)
J Infect Dis
, vol.186
, pp. 379-388
-
-
Mayer, J.1
Doubek, M.2
Doubek, J.3
Horky, D.4
Scheer, P.5
Stepanek, M.6
-
5
-
-
0037118677
-
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS
-
Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105-9.
-
(2002)
Ann Intern Med
, vol.137
, Issue.2
, pp. 105-109
-
-
Johnson, P.C.1
Wheat, L.J.2
Cloud, G.A.3
Goldman, M.4
Lancaster, D.5
Bamberger, D.M.6
-
6
-
-
0036177170
-
Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
-
Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother. 2002;49(Suppl 1):81-6.
-
(2002)
J Antimicrob Chemother
, vol.49
, Issue.SUPPL. 1
, pp. 81-86
-
-
Cagnoni, P.J.1
-
7
-
-
33646836577
-
What is the current and future status of conventional amphotericin B?
-
Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006;27(Suppl 1):12-6.
-
(2006)
Int J Antimicrob Agents
, vol.27
, Issue.SUPPL. 1
, pp. 12-16
-
-
Kleinberg, M.1
-
8
-
-
12144289618
-
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients
-
Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant. 2004;33:543-8.
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 543-548
-
-
Miller, C.B.1
Waller, E.K.2
Klingemann, H.G.3
Dignani, M.C.4
Anaissie, E.J.5
Cagnoni, P.J.6
-
9
-
-
40649108887
-
Renal impairment and amphotericin B formulations in patients with invasive fungal infections [review]
-
Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections [review]. Med Mycol. 2008;46:97-112.
-
(2008)
Med Mycol
, vol.46
, pp. 97-112
-
-
Saliba, F.1
Dupont, B.2
-
10
-
-
1942436895
-
Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - A randomized, controlled trial
-
Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol. 2004;72:342-7.
-
(2004)
Eur J Haematol
, vol.72
, pp. 342-347
-
-
Subira, M.1
Martino, R.2
Gomez, L.3
Marti, J.M.4
Estany, C.5
Sierra, J.6
-
11
-
-
0033545538
-
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
-
National Institute of Allergy and Infectious Diseases Mycoses Study Group
-
Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-71.
-
(1999)
N Engl J Med
, vol.340
, pp. 764-771
-
-
Walsh, T.J.1
Finberg, R.W.2
Arndt, C.3
Hiemenz, J.4
Schwartz, C.5
Bodensteiner, D.6
-
12
-
-
0038282815
-
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [review]
-
Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EJ, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [review]. Clin Ther. 2003;25:1295-320.
-
(2003)
Clin Ther
, vol.25
, pp. 1295-1320
-
-
Barrett, J.P.1
Vardulaki, K.A.2
Conlon, C.3
Cooke, J.4
Daza-Ramirez, P.5
Evans, E.J.6
-
13
-
-
4444253717
-
Amphotericin B: Is a lipidformulation gold standard feasible [letter]?
-
author reply 6-7
-
Spellberg B, Witt MD, Beck CK. Amphotericin B: is a lipidformulation gold standard feasible [letter]? Clin Infect Dis. 2004;38:304-5. author reply 6-7.
-
(2004)
Clin Infect Dis
, vol.38
, pp. 304-305
-
-
Spellberg, B.1
Witt, M.D.2
Beck, C.K.3
-
14
-
-
0035282477
-
Mortality and costs of acute renal failure associated with amphotericin B therapy
-
Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686-93.
-
(2001)
Clin Infect Dis
, vol.32
, pp. 686-693
-
-
Bates, D.W.1
Su, L.2
Yu, D.T.3
Chertow, G.M.4
Seger, D.L.5
Gomes, D.R.6
-
15
-
-
0034045794
-
Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
-
Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000;18:2476-83.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2476-2483
-
-
Cagnoni, P.J.1
Walsh, T.J.2
Prendergast, M.M.3
Bodensteiner, D.4
Hiemenz, S.5
Greenberg, R.N.6
-
16
-
-
18744376299
-
Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity
-
Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis. 2002;35:e120-7.
-
(2002)
Clin Infect Dis
, vol.35
-
-
Harbarth, S.1
Burke, J.P.2
Lloyd, J.F.3
Evans, R.S.4
Pestotnik, S.L.5
Samore, M.H.6
-
17
-
-
32144458558
-
Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes
-
Garbino J, Markham L, Matulionyte R, Rives V, Lew D. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes. Scand J Infect Dis. 2006;38:110-3.
-
(2006)
Scand J Infect Dis
, vol.38
, pp. 110-113
-
-
Garbino, J.1
Markham, L.2
Matulionyte, R.3
Rives, V.4
Lew, D.5
-
20
-
-
0033062226
-
Must we really fear toxicity of conventional amphotericin B in oncological patients?
-
Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer. 1999;7:51-5.
-
(1999)
Support Care Cancer
, vol.7
, pp. 51-55
-
-
Mayer, J.1
Doubek, M.2
Vorlicek, J.3
-
21
-
-
33846973373
-
Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: Lower toxicity with suitable premedication
-
Oto OA, Paydas S, Disel U, Yavuz S, Seydaoglu G. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. Mycoses. 2007;50:135-9.
-
(2007)
Mycoses
, vol.50
, pp. 135-139
-
-
Oto, O.A.1
Paydas, S.2
Disel, U.3
Yavuz, S.4
Seydaoglu, G.5
-
23
-
-
60549098868
-
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
-
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
-
(2009)
Clin Infect Dis
, vol.48
, pp. 503-535
-
-
Pappas, P.G.1
Kauffman, C.A.2
Andes, D.3
Benjamin Jr., D.K.4
Calandra, T.F.5
Edwards Jr., J.E.6
-
24
-
-
3242782339
-
Empirical antifungal therapy in treating febrile neutropenic patients
-
Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39(Suppl 1):S38-43.
-
(2004)
Clin Infect Dis
, vol.39
, Issue.SUPPL. 1
-
-
Wingard, J.R.1
-
25
-
-
0035816268
-
Body surface area estimation in children using weight alone: Application in paediatric oncology
-
Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer. 2001;85:23-8.
-
(2001)
Br J Cancer
, vol.85
, pp. 23-28
-
-
Sharkey, I.1
Boddy, A.V.2
Wallace, H.3
Mycroft, J.4
Hollis, R.5
Picton, S.6
-
26
-
-
79952193176
-
Amphotericin B in neonates: Deoxycholate or lipid formulation as first-line therapy - Is there a 'right' choice?
-
Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? Curr Opin Infect Dis. 2011;24:163-71.
-
(2011)
Curr Opin Infect Dis
, vol.24
, pp. 163-171
-
-
Turkova, A.1
Roilides, E.2
Sharland, M.3
-
27
-
-
39449095735
-
Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America
-
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 327-360
-
-
Walsh, T.J.1
Anaissie, E.J.2
Denning, D.W.3
Herbrecht, R.4
Kontoyiannis, D.P.5
Marr, K.A.6
|